Articles tagged with Lung Cancer
The study identified inactivating mutations in the B2M gene, which codes for a protein involved in the immune response. In lung cancer patients, higher levels of B2M expression correlate with improved response to immunotherapy.
A new Yale study suggests that delaying chemotherapy after lung cancer surgery can lead to similar outcomes and lower risk of death. The research found that initiation between 57-127 days post-surgery had a similar impact as traditional timing, indicating a potential benefit for patients.
A study by Yale researchers found that older lung cancer patients can spend an average of one in three days interacting with the healthcare system within the first 60 days after surgery or radiation therapy. Patients with a higher number of medical conditions treated with surgery had the most post-treatment burdens.
A recent study published in JAMA Oncology suggests that chemotherapy can still benefit patients with non-small-cell lung cancer who recover slowly from surgery. The study found that delaying chemotherapy by up to four months did not increase the risk of death and may even lower it compared to earlier treatment.
A new study by UNC School of Medicine found that only 49.8% of surveyed teens consider cigar warnings 'very believable', highlighting the need for improved tobacco prevention campaigns. The survey, which included 1,125 adolescents aged 13-17, suggests that graphic warnings may be more effective in engaging youth.
Patients with advanced non-small-cell lung cancer survived four months longer on immunotherapy drug atezolizumab compared to chemotherapy, with atezolizumab also having fewer side effects. The trial found that the drug worked best for patients with high levels of PD-L1 protein, doubling their survival.
A new blood test may provide a cheap and effective way for doctors to manage lung cancer by analyzing genetic profiles of tumor cells in patient blood samples. The test is safer, cheaper, faster, and more effective than alternative diagnostic approaches, costing less than $30.
French researchers report harmonization study on PD-L1 immunohistochemistry testing in NSCLC. Durvalumab shows clinical activity and well-tolerability in heavily-pretreated patients with NSCLC. Patients receiving pembrolizumab report better quality of life than those on chemotherapy.
Researchers discovered a subset of lung tumors sensitive to MEK inhibitors, offering new hope for up to 10% of lung cancer patients with ATM mutant gene. The study's findings could pave the way for precision medicine and targeted treatment strategies.
A new study found that cancer cases are growing at an alarming rate in less developed countries, with a 50% increase between 2005 and 2015. The global burden of disease is heaviest for countries with high development levels, but the most rapid escalation can be seen in low-income nations where health services are often lacking.
Public health advocates from around the world are using various tactics to reduce tobacco company influence, including pension fund reform and smoke-free legislation. Efforts have shown positive impacts on public health, such as a 13% decrease in all-cause mortality in Ireland.
Researchers and patient advocates emphasize the importance of new care models in combating lung cancer. Dr. Laurie Gaspar discusses the benefits of shared decision-making and Patient Decision Aids, while Dr. Raymond Osarogiagbon highlights the effectiveness of Center of Excellence programs in underserved areas.
The study estimates 17.5 million cancer cases and 8.7 million cancer-related deaths worldwide in 2015, with prostate cancer being the most common in men and breast cancer in women. The report also highlights an increase in cancer incidence due to aging and demographic changes.
A study comparing four tests for PD-L1 expression has found that three tests cluster together, but the results vary with different scales. The goal of the ongoing study is to determine which test predicts treatment response most accurately.
Heavy smokers with diabetes are at increased risk of death from causes other than lung cancer, according to a study published in the Radiological Society of North America. The study found that participants with diabetes had a doubled risk of all-cause mortality and non-lung cancer mortality compared to those without diabetes.
Researchers at the University of Texas MD Anderson Cancer Center have discovered a link between the Golgi apparatus and lung cancer metastasis. The study found that targeting certain proteins in the Golgi can prevent tumor cells from spreading, offering a new potential therapeutic approach for preventing metastasis.
A new index called Lung-moIGPA has been developed to estimate survival in patients with non-small cell lung cancer and brain metastases. The updated Lung-moIGPA incorporates genetic and molecular data, including EGFR and ALK gene mutations, and predicts an overall median survival of 12 months.
A study of 101 advanced lung cancer patients found that hybrid capture-based next-generation sequencing (HC-based NGS) identified clinically actionable genomic alterations (GAs) in 50% of patients, leading to changes in treatment strategy. The overall response rate to targeted therapies was 65%, with median survival not yet reached.
Lung cancer is expected to result in an estimated 158,080 deaths in 2016 due to limited treatment options. Researchers are exploring signals within lung cancer cells that cause them to grow quickly and spread to other organs like the liver.
Researchers at MD Anderson Cancer Center have developed a new tool to predict lung cancer risk in never, light, and heavy smokers. By incorporating various risk factors, the model can better classify those in greatest need of lung cancer screening, thereby reducing unnecessary screenings and false positives.
Researchers found that beta-cryptoxanthin inhibits nicotine-linked lung cancer development in mouse models, reducing tumor number and invasiveness. The study suggests that eating foods high in BCX may have a beneficial effect on lung cancer risk for smokers and tobacco product users.
Researchers found higher levels of estrogen in lung tissue of postmenopausal women with synchronous multiple lung adenocarcinoma (SMLA) compared to those with single tumor lung adenocarcinoma. The study suggests an association between estrogen and SMLA, potentially leading to gene therapy development.
Researchers have broken down lung cancer into distinct subtypes with unique molecular profiles, suggesting potential for personalized therapies. The study identifies specific subsets of cancer cells that may be responsive to immunotherapy, a promising approach for treating the disease.
A randomized controlled trial found that preoperative high-intensity interval training improved aerobic performance in patients with operable non-small cell lung cancer. However, it did not significantly reduce postoperative complications or mortality rates.
A recent study reveals that blood-based genomic and proteomic testing can rapidly identify genetic mutations in patients with lung cancer, enabling personalized treatment. This approach significantly reduces the wait period between diagnosis and treatment, improving patient outcomes.
A team of researchers at the Salk Institute has found a way to obstruct the creation of fat molecules in cancer cells, stalling their growth. This approach involves inhibiting an enzyme called Acetyl-CoA Carboxylase, which is crucial for lipid synthesis activity.
A phase III trial found that MEK inhibition with selumetinib plus docetaxel did not improve progression-free or overall survival in KRAS-mutant non-small-cell lung cancer patients. The study concluded that there is a desperate need for new treatments for this subset of NSCLC patients.
The OAK study found a 27% improvement in overall survival for patients treated with atezolizumab compared to docetaxel, regardless of PD-L1 expression levels. This benefit was seen across different tumor histologies and even among patients with no PD-L1 expression.
The ASCEND-5 study showed ceritinib significantly improved progression-free survival compared to chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement. Ceritinib also increased overall response rate, but did not improve overall survival.
In the ASCEND-5 study, ceritinib significantly improved progression-free survival compared to chemotherapy in patients with non-small-cell lung cancer harbouring an ALK rearrangement. The primary endpoint was a median progression-free survival of 5.4 months with ceritinib versus 1.6 months with chemotherapy.
Researchers observed a significantly greater objective response rate (55% vs. 29%) in patients who received pembrolizumab as well as chemotherapy, compared to those treated with chemotherapy alone. Participants also experienced an improved progression-free survival (median 13.0 months vs. 8.9 months) in the pembrolizumab arm.
Researchers found that neoadjuvant immunotherapy with nivolumab was safe and did not delay surgery in patients with early-stage non-small-cell lung cancer. Six of 15 patients experienced major pathological regression, suggesting potential activity of anti-PD-1 immunotherapy in early stage lung cancer.
The study found that surgery performed within 6-9 weeks after neoadjuvant chemoradiation therapy (NCRT) correlates with increased risk of poor outcomes, including perioperative mortality and overall survival. In contrast, an optimal interval of less than 8 weeks is recommended to minimize risks associated with radiation pneumonitis.
A study published in JAMA compared five-year survival rates after endosonography and mediastinoscopy for mediastinal nodal staging of lung cancer. The endosonographic strategy was found to be more sensitive for diagnosing mediastinal nodal metastases.
Researchers found that a ginger compound, 6-ginergol, can lower cancer risk when combined with capsaicin, the active ingredient in chili peppers. In mouse studies, only 20% of mice developed lung carcinomas after receiving both compounds, compared to 50% with capsaicin alone.
Sumitra Thongprasert has been awarded the second ESMO Women for Oncology award for her role as a role model for women in oncology. The award acknowledges her advocacy across Asia for female participation in the oncology workforce and promotion of women in leadership positions.
Researchers found that whole brain radiotherapy had no beneficial effect on survival or quality of life compared to best supportive care and steroids. The trial included 538 patients with non-small cell lung cancer who had spread to the brain, and showed that WBRT did not extend survival or improve quality of life.
A study published in Nature found that excess fumarate resulting from enzyme loss leads to epigenetic changes promoting epithelial-to-mesenchymal transition, a process driving tumor metastasis. This understanding may provide key strategies for cancer therapy targeting metastasis caused by fumarate accumulation.
A University of Louisville researcher found that having children in the home does not prompt parents to test for radon and secondhand smoke, both major contributors to lung cancer. Radon and tobacco smoke have synergistic effects, increasing lung cancer risk, especially in Kentucky where incidence rates are highest.
A nationwide study in England has collected data on 30-day mortality for patients with breast and lung cancer treated with chemotherapy, identifying factors such as age, general well-being, and NHS trusts with higher-than-expected rates of mortality. The study aims to improve patient care and inform clinical decision-making.
Researchers identified genetic markers associated with a fast rate of nicotine metabolism in smokers, leading them to smoke more cigarettes to maintain stable nicotine levels. This finding could identify smokers at greater risk for lung cancer, enabling doctors and public health leaders to improve prevention strategies.
A large cohort of NSCLC patients with M1a disease found lymph node staging to have clinical significance and an impact on prognosis. The results showed that patients without regional lymph node metastasis (N0) had better lung cancer-specific survival rates compared to those with N1 or N2 disease. Lymph node involvement also emerged as ...
Patients who initially screened negative for lung cancer but developed the disease one to two years later had more aggressive disease, according to a new study by researchers at Moffitt Cancer Center. The study highlights the importance of continued lung cancer screening in high-risk patients.
A study of over 14,000 childhood cancer survivors reveals a significant increase in cumulative incidence of lung complications up to 25 years after diagnosis. The findings highlight the need for follow-up health care and suggest potential impacts on quality of life.
A study found that NSCLC patients with EGFR mutations had longer overall survival when treated with tyrosine kinase inhibitors (TKIs) for leptomeningeal metastases, compared to those without TKI therapy. Chemotherapy was also associated with prolonged survival in these patients.
The USC Cancer Report Card highlights the decline of prostate and lung cancer among men, while stomach cancer is on the rise globally. Breast cancer risk increases for women, particularly Korean women, due to westernized lifestyles. The report also shows that many cancers are preventable and curable if caught early.
A population-based study found that air pollution may shorten the survival of patients with lung cancer, especially those with early stage disease. The study tracked over 352,000 people with lung cancer and found that higher exposure to pollutants like nitrogen dioxide and particulate matter was associated with shorter survival times.
Researchers identified ACSL3 as essential for mutant KRAS gene activity in lung cancer cells, leading to cell death when suppressed. The study provides a critical role for fatty acids in lung cancer and meets an urgent need for targeted therapies.
The UK Lung Cancer Screening randomized controlled trial found that CT screening did not cause unnecessary anxiety, despite fear and stigma being barriers to participation. The trial recruited over 4,000 participants aged 50-75 at high risk of lung cancer, with a significant reduction in deaths for those who received screening.
Researchers developed liquid biopsies to detect EGFR mutations in urine, plasma, and blood samples. The tests showed high sensitivity and specificity for identifying patients suitable for targeted treatment and predicting cancer recurrence.
Researchers identify unique immune cells that enhance anti-tumor T cell responses in early-stage lung cancer. These hybrid neutrophils may help stimulate natural protection against tumor development.
A new minimally invasive surgical approach for lung cancer patients has shown promise in reducing bleeding risk and post-operative pain. The VATS lobectomy procedure uses ultrasonic energy to seal pulmonary arteries, allowing for faster recovery times and potentially improving survival rates.
A new study confirms that annual follow-up with low-dose computed-tomography (CT) scans is sufficient for some lung nodules, eliminating the need for biopsy or surgery. The findings suggest that these nodules can be safely monitored and do not require immediate treatment.
The College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology announced a revised evidence-based guideline for molecular testing in lung cancer patients. The guidelines aim to improve patient selection and targeted therapies.
A Yale-led study found that the EGFR cancer gene silences tumor suppressor genes in lung and glioblastoma brain cancers using a common mechanism. This discovery informs future research directions and may help determine how effective treatments will be against different EGFR mutations.
Researchers found that combining radiotherapy with PD-1 blockade therapy improved survival rates in a murine lung cancer model. However, this treatment approach showed no benefits for tumors that had relapsed after radiation therapy, highlighting the need for personalized medicine strategies.
A recent survey found that less than half of family physicians believe that lung cancer screening using low-dose computed tomography (LDCT) reduces lung cancer-related deaths. Despite the American Cancer Society's support for LDCT screening, many physicians are unsure about current recommendations.
A large cohort of 29,908 patients with pathologic stage T2N0M0 NSCLC showed improved median overall survival and 5-year OS when receiving adjuvant chemotherapy. The study demonstrated a benefit from adjuvant chemotherapy in patients with completely resected stage T2N0M0 NSCLC regardless of tumor size.
A study analyzing over 34,000 lung cancer patients in England found that those aged 50-64 are more likely to be diagnosed at a late stage compared to older age groups. Younger patients in their 70s are more likely to be diagnosed with early-stage disease.
A new breath test has been developed to identify lung cancer after surgery, using a simple, affordable process that analyzes carbonyl volatile organic compounds in exhaled breath. The test shows great potential for detecting lung cancer at any point, both as primary screening and post-surgery monitoring.